Management of Polycythemia Vera

Initial Management Approach

• The American Society of Hematology recommends therapeutic phlebotomy to maintain hematocrit below 45%, which has been shown to significantly reduce thrombotic risk 1, 2
• Low-dose aspirin (100 mg daily) should be prescribed for all patients unless contraindicated, as it significantly reduces thrombotic events without substantially increasing bleeding risk 1, 2

Risk Stratification

• High-risk patients include those with age ≥60 years, history of prior thrombosis, poor tolerance of phlebotomy, symptomatic or progressive splenomegaly, severe disease-related symptoms, platelet count >1,500 × 10^9/L, or progressive leukocytosis 1, 2

Cytoreductive Therapy

• Cytoreductive therapy is indicated for all high-risk patients, with first-line options including hydroxyurea, interferon alfa, and pegylated interferon 1, 2
• The National Comprehensive Cancer Network recommends hydroxyurea as a first-line cytoreductive agent, but it should be used with caution in younger patients (<40 years) 1, 2

Monitoring Response

• Response to therapy should be monitored using European LeukemiaNet criteria for clinicohematologic response, with complete response defined as hematocrit <45% without phlebotomy, platelet count <400 × 10^9/L, WBC count <10 × 10^9/L, and no disease-related symptoms 1, 2

Special Considerations

• Cautious iron supplementation may be considered in symptomatic iron-deficient patients, but requires close monitoring as it may increase red cell production 3
• For patients with intractable pruritus, interferon-α may be particularly effective, as recommended by the European Hematology Association 4